BIRD-C

BG Cancer Immunotherapy


BIRD-C is developing a novel BG Cancer Immunotherapy (BGCI) based on selected BGs loaded with chemotherapeutics such as Oxaliplatin. The therapy is given through intratumoral injection or applied in close proximity to the tumor.

BGCI destroys cancer cells through targeted delivery and release of chemotherapeutics and the induction of an immune reaction against the tumor through released fragments of cancer cells killed by the chemotherapeutic in combination with the adjuvant effect of BGs. The therapy is targeting the primary tumor as well as metastases throughout the body. BGCI aims to significantly reduce or cure the tumor burden resulting in improved quality of life by extended periods of stable disease, cancer remission, and temporary and/or permanent disease free status.

BIRD-C’s initial targets are Head & Neck Squamous Cell Carcinoma (HNSCC) and Peritoneal Carcinomatosis (PC), two markets with high potential, relatively low competition and high unmet need. HNSCC is estimated to newly affect 650,000 people per annum and forecast to reach sales of about USD 2bn in 2017. For PC an annual BGCI patient population of about 890,000 can be calculated. For these patients, with a median survival of 3 to 6 months, no therapy, except palliative chemotherapy, exists and BGCI could thus represent a paradigm shift in PC treatment.

Over the past years BIRD-C has generated lots of data that testifies for the feasibility of the BGCI approach to have a game-changing impact not only on HNSCC and PC therapy, but also other solid tumors. The company is currently raising funds to conduct pre-clinical and clinical trials in both indication areas.

 

BG cancer immunotherapy

Therapeutic concept of BGCI: Induction of immunogenic cell death leads to release of DAMPs. These beacon signals increase migration of dendritic cells (DC) into the tumor microenvironment and induce phagocytosis of released tumor antigens. Released DAMPs bind to Toll-like receptor (TLR)-4 on the surface of DC triggering their maturation which is critical for optimal antigen presentation to T cells and stimulation of tumor antigen-specific immune response leading to elimination of residual cancer cells. Oxaliplatin and Doxorubicin are capable of inducing immunogenic cell death. Intratumoral administration of BGs loaded with chemotherapeutics, able to trigger immunogenic cell death, should enhance the drug-mediated toxic effect on cancer cells, and increase the presence of endogenous tumor antigens released from cancer cells dying the immunogenic pathway.

 

Immune responses stimulated by BGs and antigens delivered by BGs

Innate immune response

Induced expression of antimicrobial peptides
Induced secretion of pro-inflammatory cytokines

 

Humoral
Adaptive immune response
Antigen-specific immune response

Protective immunity against homologous challenge
Long-lasting protective immunity

Cross-protective immunity against heterologous serovars

 

Cellular
Adaptive immune response
CD4+ T cell immune response

CD8+ T cell immune response

CD4+ and CD8+ T cell immune response

 

 

 

 

immunotherapy

 

 

The BGCI approach. Administration of BGs loaded with chemotherapeutic drugs capable of inducing immunogenic cell death intratumorally (HNSCC) or intraperitoneally (PC) will lead to induction of immunogenic cancer cell death and enhanced release of tumor antigens from dying cancer cells.

 

 

 

 

 

Last update: waiting for actual data ...